Study/year | Patients | Gender (male,%) | Interventions | Cord injury level | Tetraplegia | Paraplegia | AIS | Study design | |||
---|---|---|---|---|---|---|---|---|---|---|---|
Cervical | Thoracic | Lumber | A/B | C/D/E | |||||||
Ahlquist et al. 2020 [16] | 79 | 61.0 | LMWH (40 mg daily)/UFH (5000 U twice daily) | 49 | 28 | 2 | - | - | 44 | 46 | Retrospective cohort study |
Hamidi et al. 2019 [17] | 810 | 58.0 | LMWH | 98 | 189 | 175 | - | - | - | - | Retrospective cohort study |
DOACs | 57 | 74 | 95 | ||||||||
Worley et al. 2008 [18] | 79 | 49.0 | LDUH (heparin 5000 U twice daily) | - | - | - | 35 | 12 | 24 | 23 | Retrospective cohort study |
LMWH (dalteparin 5000 units daily) | 25 | 18 | 20 | 23 | |||||||
Spinal Cord Injury Thromboprophylaxis Investigators 2003 [19] | 476 | 81.7 | UFH (5000 U every 8 h) | - | - | - | 147 | 73 | 215 | 31 | Retrospective cohort study |
Enoxaparin (30 mg every 12 h) | 130 | 67 | 191 | 39 | |||||||
Thumbikat et al. 2002 [20] | 173 | 74.6 | Heparin (5000 U twice daily) | 36 | 46 | 19 | - | - | - | - | Retrospective cohort study |
Enoxaparin (40mg daily) | 38 | 24 | 10 |